Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

PURPOSE: Ceftazidime–avibactam is a novel antimicrobial combining a third-generation cephalosporin with a non-β-lactam β-lactamase inhibitor that was recently approved to treat Gram-negative hospital- and ventilator-acquired pneumonia. The use of ceftazidime–avibactam to treat Pseudomonas aeruginosa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Infect Drug Resist
Main Authors: Atkin, Stan D, Abid, Shadaan, Foster, Michael, Bose, Moumita, Keller, Ashley, Hollaway, Rita, Sader, Helio S, Greenberg, David E, Finklea, James D, Castanheira, Mariana, Jain, Raksha
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6149938/
https://ncbi.nlm.nih.gov/pubmed/30271183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S173804
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados